Pain progression at initiation of cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) is associated with a poor prognosis: a post-hoc analysis of PROSELICA.

被引：0
|
作者：
Delanoy, Nicolas
De Bono, Johann S.
Mercier, Florence
Geffriaud-Ricouard, Christine
Eisenberger, Mario A.
Oudard, Stephane
机构：
[1] Georges Pompidou European Hosp, Dept Med Oncol, Paris, France
[2] Royal Marsden Hosp, London, England
[3] Inst Canc Res, London, England
[4] Soc Stat Proc, Port Mort, France
[5] Sanofi, Europe Med Oncol, Paris, France
[6] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[7] Georges Pompidou Hosp, Paris, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5558
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Pain Progression at Initiation of Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Post Hoc Analysis of the PROSELICA Study
    Delanoy, Nicolas
    Robbrecht, Debbie
    Eisenberger, Mario
    Sartor, Oliver
    de Wit, Ronald
    Mercier, Florence
    Geffriaud-Ricouard, Christine
    de Bono, Johann
    Oudard, Stephane
    CANCERS, 2021, 13 (06) : 1 - 13
  • [2] Pain progression at initiation of chemotherapy in metastatic castration-resistant prostate cancer (mCRPC) is associated with a poor prognosis: A post-hoc analysis of FIRSTANA
    Delanoy, N.
    Robbrecht, D.
    Fizazi, K.
    Mercier, F.
    Sartor, O.
    De Wit, R.
    Oudard, S.
    ANNALS OF ONCOLOGY, 2019, 30
  • [3] Cabazitaxel for octogenarian patients with metastatic castration-resistant prostate cancer (MCRPC)
    Tralongo, P.
    Bordonaro, S.
    Di Lorenzo, G.
    Borsellino, N.
    Facchini, G.
    Rossetti, S.
    Martelli, V.
    Longo, V.
    Tralongo, A. C.
    Caspani, F.
    Tuzi, A.
    Spada, M.
    Calvani, N.
    Carlini, P.
    De Giorgi, U. F. F.
    ANNALS OF ONCOLOGY, 2019, 30
  • [4] Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial
    Meisel, Alexander
    von Felten, Stefanie
    Vogt, Deborah R.
    Liewen, Heike
    de Wit, Ronald
    de Bono, Johann
    Sartor, Oliver
    Stenner-Liewen, Frank
    EUROPEAN JOURNAL OF CANCER, 2016, 56 : 93 - 100
  • [5] Post hoc responder analysis of health-related quality of life (HRQL) in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel in the phase III PROSELICA and FIRSTANA trials
    Vuillemin, A. Thiery
    Fizazi, K.
    Sartor, O.
    Oudard, S.
    Bury, D.
    Guillonneau, S.
    Ozatilgan, A.
    Eisenberger, M.
    de Bono, J. S.
    ANNALS OF ONCOLOGY, 2018, 29 : 281 - 281
  • [6] High levels of circulating ceramides are associated with poor prognosis in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Cattrini, C.
    Manfredi, M.
    Barboro, P.
    Ghirimoldi, M.
    Mennitto, A.
    Martini, V.
    Battioni, A.
    Le Van, M.
    Biello, F.
    Platini, F.
    Ruffilli, B.
    Branni, C.
    Tassone, A.
    Gobbato, S.
    Stella, A.
    Catalano, F.
    Zanardi, E.
    Pinato, D. J.
    Boccardo, F.
    Gennari, A.
    ANNALS OF ONCOLOGY, 2022, 33 (08) : S1403 - S1404
  • [7] Treatment of metastatic castration-resistant prostate cancer (mCRPC); Survival by type of progression at initiation of treatment
    Robbrecht, D. G.
    van Soest, R. J.
    Tannock, I. F.
    Oudard, S.
    Tombal, B.
    Eisenberger, M.
    Mercier, F.
    de Wit, R.
    ANNALS OF ONCOLOGY, 2018, 29
  • [8] TOLERABILITY OF CABAZITAXEL IN SENIOR ADULTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) IN EUROPE
    Heidenreich, A.
    Bracarda, S.
    Mason, M.
    Ozen, H.
    Sengelov, L.
    Gerritsen, W.
    Papandreou, C.
    Fossa, S.
    Hitier, S.
    Climent, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 307 - 307
  • [9] Cabazitaxel for metastatic castration-resistant prostate cancer (mCRPC) real data in real life
    Manneh Kopp, R.
    Alonso Gordoa, T.
    Celiz, P.
    Sepulveda, J. M.
    Grande, E.
    CastellanoGauna, D.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S499 - S500
  • [10] Combination of statin/vitamin ID and metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of two randomized clinical trials.
    de Velasco, Guillermo
    Lora, David
    Carretero-Gonzalez, Alberto
    Martin Soberon, Maria Cruz
    Sepulveda Sanchez, Juan Manuel Manuel
    Lorente, David
    Castellano, Daniel E.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345